The TP53 gene is known to act as a tumour suppressor gene in several malignancies, including colorectal carcinomas (for review, Levine et al., 1991) . Inactivation of both homologous alleles of this gene, by mutation or allele loss, may mediate one or more steps in the carcinogenesis (Friend et al., 1988) . In article I (Meling et al., 1993) , we have shown that loss of one of the TP53 gene alleles occurred in 68% of colorectal carcinomas, and that loss of this gene usually (in two thirds of the tumours with TP53 gene loss) was part of a limited, subchromosomal loss.
The purpose of a detailed classification of colorectal carcinomas is to stratify the patients into different prognostic groups, and thereby enabling the identification of those patients who should be included in a close postoperative surveillance programme, and patients who should be offered immediate adjuvant therapy. Since the introduction 60 years ago, Dukes' staging has been widely accepted for the classification of rectal carcinoma (Dukes, 1932) , and later also for classification of colonic carcinomas. The system is still the most reliable way to assess prognosis, despite several attempts of introducing additional tumour markers to improve estimation of clinical outcome (Rognum et al., 1987a; Fisher et al., 1989) . During the last decade, however, it has been shown that DNA aneuploidy is a marker of a more aggressive tumour behaviour in colorectal carcinomas, as patients with DNA aneuploid carcinomas have a significantly poorer prognosis than patients with DNA near diploid tumours (Wolley et al., 1982; Rognum et al., 1987b; . As yet, the basis for this association is not known, but specific gene alterations that are associated with DNA aneuploidy, may underlie the higher aggressiveness of these tumours (Delattre et al., 1989; Meling et al., 1991a) .
In this study we have examined the relationship between loss of heterozygosity of the TP53 gene and DNA ploidy pattern in 231 colorectal carcinomas, as well as the relationship between TP53 gene loss and clinicopathological characteristics of the tumours. Table I . Staging, grading, and evaluation of cellular atypia in the tumours was performed as described previously (Meling et al., 1991b) . aAccording to the modified Dukes' classification (Dukes, 1932; Turnbull et al., 1967) . bAccording to Morson & Sobin (1976 (Kunckel et al., 1977) . Matched tumour/normal pairs of DNA were digested with BamHI, TaqI and Pvull, respectively, and fractionated through 1% agarose gels. Southern blotting (Southern, 1975) was performed as described in article I, and the DNA was hybridised with four restriction fragment length polymorphism (RFLP) probes to chromosome 17, labelled with 32p (Feinberg & Vogelstein, 1983) . The probes applied were pBHP53 (locus symbol TP53) (H0yheim et al., 1989) , pYNZ22 (D17S30) (Nakamura et al., 1988a) , pTHH59 (D17S4) (Nakamura et al., 1988b) , and pRMU3 (D17S24) (Myers et al., 1988) . Scoring criteria are given in detail in article I.
Flow cytometric analysis Analysis of nuclear DNA content was performed on ethanol fixed single cell suspensions after nylon mesh filtration (mesh pore size 70 m) (Seidengazefabrik AG Thal, Switzerland), according to the method described by Crissman and Steinkamp (1982 Definition of aneuploidy The nuclear amount of DNA was expressed as a DNA index, giving the ratio between the mean DNA content of the cell population examined and the mean DNA content of the diploid reference cells (Hiddeman et al., 1984) . The peak in the histogram representing cells with the lowest DNA content was confirmed to represent DNA diploid cells (Meling et al., 1991b) . A tumour was classified as DNA aneuploid when a second distinct population of GI cells was present, and had a DNA index > 1.10 ( Figure 1 ) (Kirkhus et al., 1988; Meling et al., 1991b) . Otherwise the tumour was defined as DNA near diploid. For the purpose of discussing DNA indices in relation to biological relevant classifications, the tumours were also separated according to a DNA index of 1.3, and tumours with DNA index > 1.1 but < 1.3 were denoted moderately DNA aneuploid, and tumours with DNA index > 1.3, highly DNA aneuploid carcinomas.
Statistical analysis Differences in distributions were calculated by the chi-square test using Yates correction when expected value(s) was less than 5. Due to multiple independent comparisons, P-values less than 0.01 were considered to denote statistically significant differences. . (25) n.s. 17q 4% (5) 10% (7) n.s.
Amplification on 17p
11% (13) 3% (2) n.s. 17q 20% (24) 7% (5) P<0.05
No chromosome 17 alteration 15% (18) 40% (27) P < 0.0001 'AN = DNA aneuploid carcinomas, ND = DNA near diploid carcinomas.
near diploid than DNA aneuploid (P<0.0001) ( Table II) .
The DNA indices of the total 149 DNA aneuploid tumours showed a bimodal distribution, with the majority of tumours (85%, 126/149) having a DNA index > 1.3, and the remaining DNA aneuploid tumours (15%, 23/149) had DNA indices ) 1.1 and < 1.3 (Figure 2 ). The distribution of chromosome 17 alterations was analysed in these two subsets of DNA aneuploid tumours among the 189 tumours informative at both chromosome 17 arms. The tumours with DNA index > 1.1 and <1.3 (moderately DNA aneuploid) had a similar frequency of loss on 17p as the DNA near diploid carcinomas (8/19 = 42% versus 33/67 = 49%, n.s.). Of the tumours with DNA index > 1.3 (highly DNA aneuploid), 85% (88/103) had loss on 17p, which is significantly more frequent than in both moderately DNA aneuploid tumours (P<0.0001) and DNA near diploid and moderately DNA aneuploid tumours pooled together (P<0.0001).
Chromosome 17 alterations and clinicopathological characteristics There was no significant association between loss on 17p and Dukes' stage (Table III) . Amplification on 17q tended to be associated with Dukes' stage, with increasing frequency of amplification in more advanced Dukes' stages (P < 0.05) (Table III) . A significant association between loss on 17p and histological grade was found (P<0.01) (Table III) , loss on 17p being more frequent in the moderately differentiated carcinomas compared with the well -(P <0.05) and with the poorly differentiated ones (P<0.05), respectively. Increase in proportion of tumours with loss on 17p tended to be associated with increase in degree of cellular atypia (P <0.05) (Table III) . When the tumours were separated according to DNA ploidy pattern, this tendency was found in the DNA aneuploid tumour group (P<0.05), but not in the DNA near diploid tumour group (data not shown).
A significant association was found between loss on 17p and site of the tumour (for all sites, P<0.0001) (Table IV) ; loss on 17p being more frequent in tumours located in retum than in the left (P<0.01) and the right,colon (P<0.0001), respectively. Since also DNA ploidy pattern tended to be associated with tumour site (Table IV) , the tumours were separated according to DNA ploidy pattern. A significant association between loss on 17p and tumour site was found only in the DNA near diploid tumour group (P<0.0001), but not in the DNA aneuploid tumour group (Table IV) .
No significant association was found between loss on 17p and sex, as 66% (65 of 98) of tumours in female patients had loss on 17p, compared with 70% (64 of 91) of tumours in male patients (n.s.). The patients were separated according to age of less than 50 years, and of 50 years or more, respectively. There tended to be more female patients of less than 50 years that had tumours with loss on 17p (7/7, 100%), compared with female patients of 50 years or more (57/91, 63%) (P<0.05), whereas no such difference was found for male patients (data not shown). 
Discussion
We have shown that loss of heterozygosity as detected by either of the probes used on chromosome arm 17p can be regarded as loss of the TP53 gene in colorectal carcinomas. Loss on 17p can therefore be used synonymously with loss of the TP53 gene. Loss of the TP53 gene was most frequently part of a limited, subchromosomal loss. This is further discussed in article I. In this study, a highly significant association could be demonstrated between loss of the TP53 gene and DNA aneuploidy. However, this association was seen only when the loss involved large parts of (most likely the whole) chromosome, but not when loss was found only on 17p. An association between loss on chromosome arm 17p and DNA aneuploidy has previously been reported (Delattre et al., 1989) , but whether this loss was 'part of a subchromosomal loss, or involved the whole chromosome was not discussed by these authors. Based on our findings, we conclude that only tumours with loss of the whole chromosome 17 are responsible for the association between loss of the TP53 gene and DNA aneuploidy. Loss of the whole chromosome 17 may result from mitotic nondisjunction (Cavenee et al., 1983) . Our findings suggest a role for the TP53 gene loss in the aneuploidisation process, possibly as a 'target' of loss of the whole chromosome 17. We cannot exclude that DNA aneuploidy only is associated with unspecific chromosome 17 monosomy in colorectal carcinomas, and not with loss of the TP53 gene in particular. However, since our results do not indicate any additional tumour suppressor gene(s) on chromosome 17 involved in colorectal carcinogenesis (as discussed in article I), we suggest that the 'target' of loss of the whole chromosome 17 in colorectal carcinomas most likely is the TP53 gene. We have previously reported loss on chromosome lp in 22% of 180 colorectal carcinomas (Meling et al., 199la) . This is in agreement with other studies (Vogelstein et al., 1988; Leister et al., 1990; Couturier-Turpin et al., 1992) , and suggets the existence of an essential genetic region on chromosome 1 involved in colorectal carcinogenesis in a subset of tumours. The loss on chromosome lp was also significantly associated with DNA aneuploidy, and a similar association was found for loss on chromosome 2p (Meling et al., 1991a) . Based on these observations, we postulate that DNA aneuploid tumours have lost more tumour suppressor genes than DNA near diploid tumours.
DNA aneuploidy, as measured by flow cytometry, is by consensus defined as the existence of one or more extra cell population(s) with aberrant cellular DNA content (Hiddeman et al., 1984) . This definition, however, may end up with a distinction between DNA diploid and DNA aneuploid cells as being a matter of methodology and a question related to the resolution of DNA measurements, rather than reflecting biological differences. Thus, pooling together DNA aneuploid tumours with very low DNA indices and tumours with high DNA indices, may preclude the revelation of significant biological associations. In our study, we have denoted tumours with DNA index > 1.1 as DNA aneuploid. The distribution of DNA indices of the 149 DNA aneuploid tumours showed a bimodal pattern, with the majority of tumours having a DNA index ) 1.3 (Delattre et al., 1989 ). The findings of significantly different proportions of tumours with TP53 gene loss in the moderately and highly DNA aneuploid carcinomas, may reflect different pathways in the carcinogenesis in these two subsets of tumours. This would be in agreement with a recently presented theory on sequential DNA aneuploidisation during colorectal carcinogenesis (Giaretti & Santi, 1990) .
Allele amplification on 17q tended to be associated with increase in tumour spread (Dukes' stage) . Chromosome 17 may share similarities with chromosome 1 in colorectal carcinomas, since both chromosomes have a high frequency of loss on the short chromosome arm, and both have amplification on the long arm. The amplication demonstrated on chromosome arm 17q may be, therefore, a late event in the development of these tumours, as has been interpreted for this genetic change on chromosome arm lq (Atkin, 1986; Couturier-Turpin et al., 1992) .
A significant association could be demonstrated between TP53 gene loss and histological differentiation, and there also tended to be an association between TP53 gene loss and degree of cellular atypia. Thus, the TP53 gene may be one of the factors associated with morphological transformation of the mucosa cells during colorectal carcinogenesis. Furthermore, since DNA aneuploidy is also associated with increasing degree of cellular atypia (Meling et al., 1991b) , tumours with severe atypia may have a higher frequency of genetic alterations, and, therefore, possibly higher genetic instability (Nowell, 1982) , than tumours with less degree of cytological aberrations.
The proportion of tumours with loss of the TP53 gene as well as with DNA aneuploidy increased markedly towards the distal part of the large bowel. This observation might reflect different carcinogenic mechanisms for carcinomas of the colon and rectum, in agreement with earlier reports (Delattre et al., 1989; Bufill, 1990) . The cluster of DNA near diploid carcinomas without loss of the TP53 gene in the right colon is interesting, since hereditary non-polyposis colon cancers are also most frequently located in this part of the colon (Lynch et al., 1985) , and since it has recently been reported that the majority of hereditary non-polyposis carcinomas is DNA near diploid (Kouri et al., 1990; Frei et al., 1992) . Our observations may, therefore, indicate that the TP53 gene is not the gene associated with this syndrome. Studies are under way in our laboratory to further clarify this question. Both the DCC gene on chromosome 18 (Fearon et al., 1990 ) and the APC gene on chromosome 5 (Groden et al., 1991; Nishisho et al., 1991) have previously been excluded as the gene responsible for hereditary nonpolyposis cancer (Peltomaki et al., 1992) . Furthermore, the DNA indices reported for the hereditary non-polyposis carcinomas were mainly between 1.0 and 1.3 (Kouri et al., 1990) , further emphasising the importance of questioning where to draw the biologically relevant border between DNA near diploid and DNA aneuploid carcinomas.
We have recently demonstrated that 30% of colorectal carcinomas have allele amplification within the Retinoblastoma (Rbl) gene (Meling et al., 1991a) , suggesting a role for this gene in carcinogenesis in the colorectum. The tumours with loss of the TP53 gene more frequently had Rbl gen amplification than tumours without TP53 gene loss (P < 0.01, data not shown). However, this may be explained by the association between TP53 gene loss and DNA aneuploidy and between Rbl gene amplification and DNA aneuploidy, respectively, since no association could be demonstrated between TP53 gene loss and Rbl gene amplification in the DNA near diploid and the DNA aneuploid tumour group, respectively (data not shown).
We conclude that DNA aneuploidy may not represent a causal factor in carcinogenesis, but rather a marker of underlying genetic changes, as for instance loss of tumour suppressor genes. Since TP53 gene loss was associated both with DNA aneuploidy, with more deranged cytological features, as well as with left sided tumours, a role for this gene also for tumour aggressiveness is suggested. Further studies regarding this question are in progress in our laboratory.
